Gene expression derived from alternative promoters improves prognostic stratification in multiple myeloma

Luis V. Valcárcel1,2 · Ane Amundarain1,3 · Marta Kulis4,5 · Stella Charalampopoulou4,5 · Ari Melnick6 · Jesús San Miguel1,3,7 · José I. Martín-Subero2,3,5,8,9 · Francisco J. Planes2 · Xabier Agirre1,3 · Felipe Prosper1,3,7

Received: 5 November 2020 / Revised: 8 April 2021 / Accepted: 26 April 2021 / Published online: 10 May 2021
© The Author(s) 2021. This article is published with open access

Abstract
Clinical and genetic risk factors are currently used in multiple myeloma (MM) to stratify patients and to design specific therapies. However, these systems do not capture the heterogeneity of the disease supporting the development of new prognostic factors. In this study, we identified active promoters and alternative active promoters in 6 different B cell subpopulations, including bone-marrow plasma cells, and 32 MM patient samples, using RNA-seq data. We find that expression initiated at both regular and alternative promoters was specific of each B cell subpopulation or MM plasma cells, showing a remarkable level of consistency with chromatin-based promoter definition. Interestingly, using 595 MM patient samples from the CoMMpass dataset, we observed that the expression derived from some alternative promoters was associated with lower progression-free and overall survival in MM patients independently of genetic alterations. Altogether, our results define cancer-specific alternative active promoters as new transcriptomic features that can provide a new avenue for prognostic stratification possibilities in patients with MM.

Introduction
Multiple myeloma (MM) is a hematological malignancy characterized by an abnormal accumulation of clonal plasma cells (PC) in the bone marrow. In recent years, the survival of MM patients has increased significantly [1] but, regrettably, MM is still considered an incurable disease [2]. Given the underlying heterogeneity of MM, and in spite of the clinical value of genetic alterations [3], the discovery of novel biomarkers to further improve its prognostic stratification remains challenging. Several studies have attempted to address this issue using different high-throughput-
technologies [3]. While the study of the transcriptome using RNA-seq is very common in cancer research, it is not currently applied as a risk stratification tool in patients with MM [4].

Recently, Demircioğlu et al. [5] presented a novel approach to study transcriptome regulation in cancer cells, defining gene active promoters (AP) from RNA-seq data and showing that expression derived from alternative active promoters (AAP) can be used as a biomarker to improve the stratification of cancer patients. Inspired by this approach, we have exploited RNA-seq data from B-cells and MM patients to investigate the possible role of AAP as a new prognostic biomarker for improving the survival stratification of MM patients.

**Methods**

**Promoter activity definition**

We used the R package proActive to identify promoters within the annotated genes in Gencode v27. Moreover, we used STAR v 2.6.1a and our strand-specific RNA-seq (ssRNA-seq) data from PC of MM patient samples (n = 32)
and normal B-cells \((n = 35)\), to identify AP (defined as the transcription amount initiated from each of the promoters related to one specific gene), and AAP (APs showing alternative usage in different conditions) in each B-cell subpopulations and PC of MM patient samples. All identified promoters were also correlated with different epigenetic marks and the genome segmentation into chromatin states in MM and B-cell populations, as described in a previous study from our group [6]. Further details are shown in Supplemental Methods.

**Survival analyses**

Survival analyses were performed with the IA14 release data of the multiple myeloma research foundation (MMRF) CoMMpass Study dataset (595 samples). Please be referred to Supplemental Methods for further information.

**Results and discussion**

Based on the strategy described by Demircioğlu et al. [5], we initially defined the AP in different B-cell subpopulations including normal PCs from healthy donors and PCs from MM patients taking the Gencode v27 annotation as reference [7]. We identified 115,496 possible promoters and defined their activity using our ssRNA-seq data by quantifying the expression that is initiated at each promoter for each B-cell subpopulation and PC, therefore identifying AP in each specific subpopulations (Supplemental data 1). Using this promoter activity, principal component analysis (PCA) revealed robust segregation of PC from the rest of B-cells including a clear distinction between normal and MM PC (Fig. 1A). Furthermore, differential analyses revealed the presence of AP specific for each B-cell subpopulation and MM PC (Fig. 1B). These results are consistent with our previous results using global gene expression [6, 7].

The accuracy of promoter activity was validated using our previously described chromatin data generated from the same populations of B cells and PC including H3K4me3 and H3K27Ac ChIP-seq data, histone marks associated with AP [6, 8]. RNA-based estimates from patient samples accurately reflect the promoter activity, as 50–75% of the APs detected in each cell subpopulation show chromatin states indicative for AP (Fig. 1C). Focusing on MM, we observed that some of these promoters were de novo AP (Fig. 1D, E), i.e., AP associated with genes expressed only in MM and not in normal B-cells, such as PRDM5, IGF1, or BMP6, among others, as we recently described [6]. These results indicate that expression and chromatin-based estimates are consistent and therefore, RNA-seq can provide, in addition to gene expression, an important estimation of the chromatin states and promoters location from which gene transcription is taking place in each cell type.

The presence of AAP in cancer has recently been associated with the transcription of different gene isoforms [5]. Interestingly, we observed that the expression of AAP was also specific to MM and B-cell subsets and that it also correlated with epigenomic data (Fig. 1C, F, Supplemental data 2). Such is the case of ARID5B, a gene that shows a shift in promoter usage throughout B cell differentiation and MM (Fig. 1G–I).

The role of the transcriptional profile in the prognosis of MM has been clearly demonstrated, and specific transcriptional signatures have been associated with specific subgroups of MM patients [9]. Based on our previous analysis, we hypothesized that expression of AAP could represent a new prognostic factor in MM, as different isoforms of the same genes may contribute to distinct clinical impact. To address this question we took advantage of the RNA-seq data of the CoMMpass study that includes 595 MM patient samples acquired at diagnosis. Following the AAP selection criteria defined by Demircioğlu et al. [5], we identified 1539 AAP within MM patient samples. We divided the cohort of MM patients into training and test datasets. Using the
training data, we performed a univariate coxph analysis for each AAP in both PFS and OS (Supplemental methods). The expression derived from 6 AAP within MM patient samples was significantly associated with PFS, and 18 AAP with OS. To avoid bias derived from differentially expressed genes, we kept AAP whose associated gene expression did not show statistical significance for PFS and/or OS, which yielded a final list of 3 AAP significantly correlated with PFS and 10 AAP with OS of MM patients (Supplemental data 3). As an example, while SLAMF7 expression was not associated with PFS or OS, a higher activity of AAP1 of SLAMF7 was associated with improved PFS and OS in MM patients (Fig. 2A–D). These results indicate that assessment of AAP may contribute to identifying new prognostic factors.

Next, using multivariate Cox regression model and stepwise model selection with Bayesian information criterion (BIC) [10], we evaluated the hazard prediction power, for both PFS and OS, of the combination between AAP and risk genetic markers in MM patients [11–15]: ISS, t(4;14), t(14;16), t(14;20), del17p, deletion of CDKN2C, del1p, amp1q and mutations of TP53. Interestingly, we detected that AAP significantly over-perform the information provided by genetic alterations in terms of PFS and OS. In the multivariate analysis, we identified ISS stage and AAP of REEP5 and SLAMF7 genes (Supplemental Fig. 1, Supplemental data 4) with independent prognostic value for PFS, and provided a predictive model whose cumulative activity discriminated 3 different risk groups (Fig. 2E, F). This was also validated in the test cohort (Fig. 2G). Regarding OS, we identified the AAP of five genes, RWDD1, SLAMF7, ACSS1, BTNG3A1, and RPL30 (Supplemental Fig. 1, Supplemental data 4) that together with the ISS stage and amplification of 1q discriminated patients with different prognosis (Fig. 2H; Supplemental Fig. 2A). Again, these factors generated a risk assessment model with four distinct risk groups for OS (Fig. 2I) in the training cohort that was validated in the test cohort (Fig. 2J; Supplemental Fig. 2B). Finally, we also performed an ANOVA test to compare the models derived from genetic risk factors only or combining genetic risk factors with AAP, finding a significant improvement for the combination of both risk factors for PFS (p-value = 2e−5) and OS (p-value = 4e−10).

In summary, in this study, we demonstrate that RNA-seq data can be exploited in a non-conventional way to identify
AP and AAP in MM and that the expression derived from AAP shows a greater contribution as a survival risk biomarker than high-risk genetic classifiers used currently in the clinical outcome of MM patients.

Acknowledgements This research was funded by grants from Instituto de Salud Carlos III (ISCIII) and co-financed by FEDER: PI16/02024, PI17/00701 and P119/01352, TRANSCAN EPICA AC16/00041, CIBERONC CB16/1200489, Spanish Ministry of Economy, Industry and Competitiveness (RTHALMY SAF2017-92632-EXP), with support from 616/C/2019 Fundación La Marató de TV3, Departamento de Salud-Gobierno de Navarra 40/2016 and Fundación Ramón Areces (PREMAMM). The study was also supported by Cancer Research UK [C355/A26819] and FC AECC and AIRC under the Accelerator Award Program, the Multiple Myeloma Research Foundation Networks of excellence 2017 Immunotherapy Program Grant Award, the International Myeloma Foundation (Brian van Novis), the Qatar National Research Fund award 7-916-3-237 and Paula and Rodger Riney Foundation. LVV was supported by PFIS (FI17/00297) award from Ministerio de Ciencia, Innovación y Universidades, Gobierno de España. These data were generated as part of the Multiple Myeloma Research Foundation Personalized Medicine Initiatives (https://research.themmrf.org and www.themmrf.org).

Author contributions Conception and design: LVV, AA, FJP, XA, and FP Development of methodology: LVV, AA, MK, AM, JIM-S, FJP, XA, and FP Acquisition of data: LVV, AA, MK, SC, FJP, and XA Analysis and interpretation of data: LVV, AA, MK, SC, JS-M, JIM-S, FJP, and XA Writing the manuscript: LVV, AA, JIM-S, FJP, XA, and FP All authors reviewed and approved the final version of the manuscript. Study supervision: FJP, XA, and FP.

Compliance with ethical standards

Conflict of interest The authors declare no competing interests.

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

References

1. Landgren O, Rajkumar SV. New developments in diagnosis, prognosis, and assessment of response in multiple myeloma. Clin Cancer Res. 2016;22:5428–33.
2. Mateos MV, Cavo M, Blade J, Dimopoulos MA, Suzuki K, Jakubowiak A, et al. Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trial. Lancet. 2020;395:132–41.
3. Walker BA, Mavrommatis K, Wardell CP, Ashby TC, Bauer M, Davies F, et al. A high-risk, double-hit, group of newly diagnosed myeloma identified by genomic analysis. Leukemia. 2019;33:159–70.
4. Braggio E, Korttum KM, Stewart AK. SnapShot: multiple myeloma. Cancer Cell. 2015;28:678–678.e1.
5. Demircioglu D, Cukuroglu E, Kindermans M, Nandi T, Calabrese C, Fonseca NA, et al. A pan-cancer transcriptome analysis reveals pervasive regulation through alternative promoters. Cell. 2019;178:1465–77.e17.
6. Ordoñez R, Kilis M, Russiñol N, Chapaprieta V, Carrasco-Leon A, García-Torre B, et al. Chromatin activation as a unifying principle underlying pathogenic mechanisms in multiple myeloma. Genome Res. 2020;30:1217–27.
7. Agirre X, Meydan C, Jiang Y, Garate L, Doane AS, Li Z, et al. Long non-coding RNAs discriminate the stages and gene regulatory states of human humoral immune response. Nat Commun. 2019;10:821.
8. Beekman R, Chapaprieta V, Russiñol N, Vilarrasa-Blasi R, Verdaguer-Dot N, Martens JHA, et al. The reference epigenome and regulatory chromatin landscape of chronic lymphocytic leukemia. Nat Med. 2018;24:868–80.
9. Garcés JJ, Simicek M, Vicari M, Brozova L, Burgos L, Bezdeková R, et al. Transcriptional profiling of circulating tumor cells in multiple myeloma: a new model to understand disease dissemination. Leukemia. 2020;34:589–603.
10. Volinsky CT, Raferty AE. Bayesian information criterion for censored survival models. Biometrics. 2000;56:256–62.
11. Binder M, Rajkumar SV, Ketterling RP, Greipp PT, Dispensieri A, Lacy MQ, et al. Prognostic implications of abnormalities of chromosome 13 and the presence of multiple cytogenetic high-risk abnormalities in newly diagnosed multiple myeloma. Blood Cancer J. 2017;7:e600.
12. Qazilbash MH, Saliba RM, Ahmed B, Parikh G, Mendoza F, Ashraf N, et al. Deletion of the short arm of chromosome 1 (del 1p) is a strong predictor of poor outcome in myeloma patients undergoing an autotransplant. Biol Blood Marrow Transpl. 2007;13:1066–72.
13. Tomás P, Miroslava V, Jiri M, Jana B, Jaroslav B, Marie J, et al. Translocation t(8;14) in multiple myeloma defines patients with very poor prognosis-single centre experience. Clin Lymphoma, Myeloma Leuk. 2015;15:e122.
14. Seckinger A, Meissner T, Moreaux J, Depeweg D, Hillengass J, Hose K, et al. Clinical and prognostic role of annexin A2 in multiple myeloma. Blood. 2012;120:1087–94.
15. Delgado J, Pereira A, Villamor N, López-Guillermo A, Rozman C. Survival analysis in hematologic malignancies: recommendations for clinicians. Haematologica. 2014;99:1410–20.